Long-term hormone use helps prostate cancer patients live longer
Posted on: Tuesday, 1 November 2005, 07:20 CST
Doctors in Canada have discovered that treating high-risk prostate cancer patients with radiation therapy and adding hormone therapy for more than one year allows patients to live longer, have better control of their prostate specific antigen levels and lowers the rate of death specifically from prostate cancer, according to a study published in the November 1, 2005, issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO.
A total of 307 patients with a PSA level greater than 20 were split into two groups, both with a similar demographic of age, Gleason score and tumor stage. The first group had 151 patients receiving hormone therapy for less than 12 months (short term) and the second set had 156 patients receiving hormone therapy for more than 12 months (long term). Both groups were treated with hormone therapy in conjunction with external beam radiation therapy.
In the long-term hormone therapy group, 62.5 percent of patients showed a greater control over their PSA level, compared with 37 percent in the short-term group. The five-year overall survival rate was 87.5 percent for the long-term group and 75 percent in the short-term group. The chance of dying of prostate cancer was reduced from 18 percent to 6 percent in the long-term group.
"Other randomized trials have shown the benefit of combining radiation and hormone therapy in the treatment of prostate cancer. However, some of those reports appear to be restricted to patients with a high Gleason score," said Eric Berthelet, M.D., lead author of the study and a radiation oncologist at the BC Cancer Agency in Victoria, British Columbia, Canada. "This study proves that long-term hormone therapy used in consort with radiation therapy improves survival rates for high-risk patients, regardless of their Gleason score or tumor stage."
On the World Wide Web:
American Society for Therapeutic Radiology and Oncology
Related Articles
- Prostate Cancer Patients On Hormone Therapy At Risk For Various Heart Diseases
- Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation for Either Prostate or Breast Cancer
- 'Encouraging' Major Responses Seen With XYOTAX(TM) in Patients With Taxane-Resistant Androgen Independent Prostate Cancer
- Cell Genesys and Medarex Announce Encouraging Follow-Up Results From a Phase 1 Combination Therapy Trial With GVAX(TM) Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010) Antibody
- Study Eyes Obesity-Prostate Cancer Link
- Radiation Management of Prostate Cancer
- High-Dose Radiation Cuts Risk of Prostate Cancer Recurrence
- Salix Announces Publication of Study Results Suggesting Balsalazide Potential in Reduction of Radiation Damage in Prostate Cancer Patients
- Reports Show Correlations of Genasense(R) Levels With Target and Biomarker Effects in Patients With Acute Myelocytic Leukemia and Prostate Cancer
- FDA Approves Drug for Prostate Cancer
User Comments (0)

RSS Feeds